WorldPharmaNews
Search ...
Home
Business
Research
Events
Regulatory
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
www.bms.com
.
Bristol-Myers Squibb RSS Channel
Filters
Display #
5
10
15
20
25
30
50
100
All
Filter
List of articles in category Bristol-Myers Squibb
Title
Published Date
Bristol-Myers Squibb Foundation to Bridge Gaps in Hepatitis C Awareness, Prevention and Care
18 February 2009
Strong Fourth Quarter Supports Excellent 2008 for Bristol-Myers Squibb
28 January 2009
Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program
28 August 2008
Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance
20 August 2008
Bristol-Myers Squibb Pharma EEIG withdraws its marketing authorisation application for DuoCover
28 May 2008
Celebrity Chef Offers Recipes and Shortcuts in the Kitchen to People with Rheumatoid Arthritis
28 February 2008
Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and 2007
01 February 2008
Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
09 January 2008
European Commission Approves ATRIPLA®
18 December 2007
Avista Capital Partners to Acquire Bristol-Myers Squibb Medical Imaging for $525 Million
18 December 2007
Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance - ATRIPLA®
13 December 2007
World Aids Day Campaign to Shine a Light of Hope on the HIV/AIDS Epidemic in the United States
28 November 2007
Bristol-Myers Squibb Company Reports Financial Results
27 October 2007
Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25
15 October 2007
Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation
29 September 2007
Bristol-Myers Squibb to Acquire Adnexus Therapeutics
25 September 2007
ERBITUX® Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
12 September 2007
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
Business & Industry
CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge
Research & Development
'Biohybrid' device could restore function in paralysed limbs
Scientists use tardigrade proteins for human health breakthrough
DNA treatment could delay paralysis that strikes nearly all patients with ALS
Scientists reveal a potential new approach to treating liver cancer
Normalizing tumor blood vessels may improve immunotherapy against brain cancer
Engineered bacteria find tumors, then alert the authorities
First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases
Conferences & Events
SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
SAE Media Group's 6th annual 3D Cell Culture Conference
CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
CPHI Excellence in Pharma Award Winners 2022
CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
FDA grants Accelerated Approval for Alzheimer's disease treatment
FDA approves new HIV drug for adults with limited treatment options
FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
FDA approves first gene therapy to treat adults with Hemophilia B
FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
You are here:
Home
Bristol-Myers Squibb